Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)
Unintended Weight Loss: While weight loss is the goal, losing weight too rapidly or due to an inability to keep food down is a cause for concern
And they activate the same downstream pathways in the liver, fat tissue, and pancreas
Trial results at the 48 week mark are expected by 4Q 2023
In a separate 68-week study directly comparing liraglutide and semaglutide for weight loss, 3 mg liraglutide resulted in an average weight loss of 6.4% of body weight , while 2.4 mg semaglutide showed a 15.8% reduction
US$ 28.02
US$ 29.48
US$ 27.20
US$ 20.84
US$ 23.75
:max_bytes(150000):strip_icc()/Health-GettyImages-2112991427-c2c4d692054b4ff6933f01fc6c5be06c.jpg)
